Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 24, 2016. The report announces the commencement of a Phase III clinical development programme for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), intended as a treatment for anaemia associated with chronic kidney disease (CKD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on clinical development milestones rather than financial performance.
Material Changes
The primary material change reported is the initiation of two pivotal Phase III studies (ASCEND-D and ASCEND-ND) for daprodustat. This follows Phase II data presented in November 2016 at the American Society of Nephrology Kidney Week congress, which characterized the dose-response relationship and safety profile of the drug.
Guidance, Outlook, and Risks
- Outlook: GSK aims to evaluate whether daprodustat is non-inferior to recombinant human erythropoietin regarding major adverse cardiovascular events (MACE) and haemoglobin changes. If non-inferiority is met, superiority for the safety endpoint will be assessed.
- Study Design:
- ASCEND-D: Enrolling approximately 3,000 dialysis-dependent subjects switching from erythropoietin-stimulating agents (ESA).
- ASCEND-ND: Enrolling approximately 4,500 non-dialysis-dependent subjects, including those switching from or naive to ESA.
- Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in the company's 2015 Annual Report on Form 20-F. Daprodustat is not currently approved for any indication.
Investor Verification Checklist
- Verify the specific clinical trial registry numbers (NCT02879305 for ASCEND-D and NCT02876835 for ASCEND-ND) for enrollment status and protocol details.
- Review the Phase II data presented at the American Society of Nephrology Kidney Week to understand the basis for the Phase III design.
- Monitor future filings for updates on the co-primary endpoints: time to first occurrence of MACE and mean change in haemoglobin.
- Assess the competitive landscape for oral HIF-PHI inhibitors in the CKD anaemia market.